Akorn gets FDA warning letter related to New Jersey plant

Akorn Inc said on Tuesday the U.S. Food and Drug Administration has raised certain issues related to its Somerset, New Jersey manufacturing facility, sending the generic drugmaker's shares down nearly 13% premarket.